The Blavatnik Fund for Innovation at Yale Awards Over $3 Million in Accelerator Funding to Develop 12 New Therapeutic and Digital Health Products
Osmol Therapeutics Announces Closing of Series A-1 Funding to Advance the Clinical Development of the First Therapy to Prevent Chemotherapy-induced Neuropathy
